VSTM Verastem Inc
Price (delayed)
$6.21
Market cap
$319.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.66
Enterprise value
$272.93M
Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on
Highlights
Verastem's EPS has decreased by 14% QoQ but it has increased by 8% YoY
Verastem's equity has shrunk by 150% YoY
VSTM's net income is down by 50% year-on-year and by 40% since the previous quarter
Key stats
What are the main financial stats of VSTM
Market
Valuations
Earnings
Shares outstanding
51.49M
Market cap
$319.73M
Enterprise value
$272.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
22.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.29
Revenue
$10M
Gross profit
$10M
Operating income
-$114.96M
Net income
-$130.64M
EBIT
-$125.89M
EBITDA
-$126.04M
Free cash flow
-$104.8M
Per share
Balance sheet
Liquidity
EPS
-$3.66
EPS diluted
-$3.66
Free cash flow per share
-$2.93
Book value per share
-$0.65
Revenue per share
$0.28
TBVPS
$2.84
Total assets
$101.54M
Total liabilities
$130.43M
Debt
$42.25M
Equity
-$28.89M
Working capital
$63.99M
Debt to equity
-1.46
Current ratio
3.07
Quick ratio
2.88
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
-1,260.4%
Gross margin
100%
Net margin
-1,306.4%
Operating margin
-1,149.6%
Return on assets
-114.3%
Return on equity
-2,003.6%
Return on invested capital
-380.9%
Return on capital employed
-178.4%
Return on sales
-1,258.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VSTM stock price
How has the Verastem stock price performed over time
Intraday
8.19%
1 week
29.92%
1 month
-6.62%
1 year
-36.89%
YTD
20.12%
QTD
2.99%
Financial performance
How have Verastem's revenue and profit performed over time
Revenue
$10M
Gross profit
$10M
Operating income
-$114.96M
Net income
-$130.64M
Gross margin
100%
Net margin
-1,306.4%
VSTM's net income is down by 50% year-on-year and by 40% since the previous quarter
Verastem's net margin has decreased by 40% from the previous quarter
The company's operating income fell by 25% YoY
Growth
What is Verastem's growth rate over time
Valuation
What is Verastem stock price valuation
P/E
N/A
P/B
N/A
P/S
22.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.29
Verastem's EPS has decreased by 14% QoQ but it has increased by 8% YoY
Verastem's equity has shrunk by 150% YoY
Efficiency
How efficient is Verastem business performance
The ROIC has plunged by 198% YoY and by 109% from the previous quarter
The ROA has plunged by 109% YoY and by 54% from the previous quarter
Verastem's return on sales has decreased by 42% QoQ
Dividends
What is VSTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VSTM.
Financial health
How did Verastem financials performed over time
The total assets is 22% smaller than the total liabilities
Verastem's total liabilities has soared by 83% YoY and by 39% from the previous quarter
Verastem's quick ratio has decreased by 45% YoY and by 5% from the previous quarter
Verastem's equity has shrunk by 150% YoY
VSTM's debt to equity has dropped by 139% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.